MDR1-EXPRESSING CD4 + T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE.

Anthony Di RoioMargaux HubertLaurie BessonMarion BossennecCéline RodriguezYenkel Grinberg-BleyerGuilhem LalleLyvia MoudombiRaphael SchneiderCyril DegletagneIsabelle TreilleuxDaniel J CampbellSéverine MetzgerThomas DuhenOlivier TrédanChristophe CauxChristine Ménétrier-Caux

Published in: Journal for immunotherapy of cancer (2023)

MDR1 favored the enrichment of Th1.17 and Th17 in blood and tumor after NAC that correlated to clinical response.

Keyphrases

neoadjuvant chemotherapy
multidrug resistant
locally advanced
lymph node
transcription factor
sentinel lymph node
squamous cell carcinoma
young adults
wild type